Table 1.
Clinical characteristics, response, and toxicity profile of patients.
| Patient | Age/sex | Cancer and stage | PD-L1 expression. Other mutation | Previous lines of therapy | Best response | Length of therapy | Toxicity (grade) | Alive or dead |
|---|---|---|---|---|---|---|---|---|
| 1 | 57/F | Lung SCC IV | <1% | Carbo Tax 2 AT - 3 doses |
NA | NA | D (PD) | |
|
| ||||||||
| 2 | 40/M | Lung ADC IV | NA | Carbo Tax 3 then Nivo 1 | NA | NA | D(sepsis) | |
|
| ||||||||
| 3 | 62/M | Lung SCC II | NA | Lobectomy then Cis Docetaxel 1 then Carbo Tax 1 then Nivo 10 | SD | 28 weeks. stopped due to pneumonitis | Pneumonitis (3) | Alive |
|
| ||||||||
| 4 | 45/M | Lung ADC IV | NA BRAF V600 |
Carbo Alimta 4 then Alimta 4 then Nivo 10 | PR | 24 and ongoing | Colitis (2) Rash (1) |
Alive |
|
| ||||||||
| 5 | 45/F | Lung ADC IV | <1% | Carbo Alimta 4 then Alimta 13 then Nivo 17 then Docetaxel | PR | 34 weeks | Alive | |
|
| ||||||||
| 6 | 56/M | Lung SCC IV | NA | Pembro 6 then Carbo Tax 2 | SD | 16 weeks | D(PD) | |
|
| ||||||||
| 7 | 55/M | Lung ADC IV | 20% HER 2 Neu |
Carbo Alimta 4 then Alimta 3 then Pembro 7 then Trastu + Pertuzumab | SD | 22 weeks | Fatigue (1) Hypothyroidism |
alive |
|
| ||||||||
| 8 | 60/M | Lung ADC IV | NA | Carbo Alimta 4 then Alimta 10 then Nivo 8 | PR | 16 and ongoing | Elevated TSH | alive |
|
| ||||||||
| 9 | 58/M | Lung mixed IV | NA | Cis Etopo x5 then Nivo 5 | PD | NA | D(PD) | |
|
| ||||||||
| 10 | 48/M | Lung ADC IV | 90% EGFR |
Erlotinib 5 months then Pembro 2 | PD | NA | D(PD) | |
|
| ||||||||
| 11 | 40/F | Anal SCC IV | NA | Chemo RT hen CarboTax 5 then Nivo 1 | NA | NA | D (PD) | |
|
| ||||||||
| 12 | 54/M | Anal SCC IV | NA | Mitomycin Xeloda then Nivo 13 | PD | 26 weeks | Hypothyroidism | D(PD) |
|
| ||||||||
| 13 | 43/M | HCC III | NA | Regorafinib 24 then Nivo 12 | SD | 25 weeks | Fatigue (1) | D(PD) |
|
| ||||||||
| 14 | 44/M | HCC IV | NA | RFA, TACE hen Soafenib 3 months then Nivo 12 | PR | 25 and ongoing | Hyperglycemia, Hypothyroidism | Alive |
|
| ||||||||
| 15 | 59/M | RCC III | NA | Sorafenib then Sunitinib then Everolimus the Nivo 11 then Axitinib | SD | 22 weeks | Elevated TSH | D(sepsis) |
|
| ||||||||
| 16 | 42/M | DLBCL IV | NA | RCHOP then RICE PBSCT then Nivo 10 then Rev Rtux 1 | PD | 22 weeks | D(PD) | |
|
| ||||||||
| 17 | 56/M | Invasive basal | NA | Vsmodegib 6 then Nivo 10 | PR | 24 weeks and ongoing | Elevated TSH | alive |
Abbreviations: SCC: squamous cell cancer. ADC: adenocarcinoma. RCC: renal cell cancer. HCC: hepatocellular cancer. DLBCL: diffuse large B cell lymphoma. Nivo: Nivolumab. Pembro: Pembrolizumab. AT: Atezolizumab. NA: not available. SD: stable disease. PR: partial response. PD: progressive disease. Carbo Tax: Carboplatin and Paclitaxel. Cis: Cisplatin. Trastu: Trastuzumab. Cis Etopo: Cisplatin Etoposide. RT: Radiation therapy. RFA: radiofrequency ablation. RCHOP: Rituximab, Cyclophosphamide, Adriamycin, Oncovin, Prednisone. RICE: Rituximab, Ifosfamide, Carboplatin, Etoposide. SCT: stem cell transplant. RR: Rituximab, Revlimid. D: Dead.